Mario Annunziata

A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs

Delphine Réa, Michael J. Mauro, Carla Boquimpani et al. · Blood · 2021 · 336 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +6

CD56 Expression Is an Indicator of Poor Clinical Outcome in Patients With Acute Promyelocytic Leukemia Treated With Simultaneous All-Trans-Retinoic Acid and Chemotherapy

Felicetto Ferrara, Fortunato Morabito, Bruno Martino et al. · Journal of Clinical Oncology · 2000 · 168 citations

Medicine, Hematology, Oncology +15

Asciminib vs bosutinib in chronic-phase chronic myeloid leukemia previously treated with at least two tyrosine kinase inhibitors: longer-term follow-up of ASCEMBL

Andreas Hochhaus, Delphine Réa, Carla Boquimpani et al. · Leukemia · 2023 · 135 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +13

Residual Peripheral Blood CD26+ Leukemic Stem Cells in Chronic Myeloid Leukemia Patients During TKI Therapy and During Treatment-Free Remission

Monica Bocchia, Anna Sicuranza, Elisabetta Abruzzese et al. · Frontiers in Oncology · 2018 · 105 citations · Full text

Medicine, Hematology, Oncology +17

Differences among young adults, adults and elderly chronic myeloid leukemia patients

Fabio Castagnetti, Gabriele Gugliotta, Michele Baccarani et al. · Annals of Oncology · 2014 · 99 citations · Full text

Medicine, Geriatric Medicine, Oncology +10